trial

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

NCTId NCT01192906
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 624 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2014-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
624 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2010-12
Primary completion
2014-07
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Bitopertin

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negat — primary completion2014-07

Facts & assertions

4 sourced
Enrollment
624
Phase
PHASE3
Primary Completion Date
2014-07
Status
COMPLETED
relationships
The graph out of here
drug
Bitopertin
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication